The research & development work of GARDP is focused on urgently needed treatments for drug-resistant bacteria on the WHO priority pathogens list.
Addressing critically underfunded & unfilled gaps in the development of treatments
GARDP is tracking, evaluating and contributing where others are not.
GARDP brings together experience and innovation from governments, the private sectors, academia and civil society to develop treatments. To ensure access to treatments for every person who needs them.
“Antibiotic resistance could lead to the end of modern medicine as we know it.”
A lack of new antibiotics
Most pharmaceutical companies are no longer working on new antibiotics.
Half of all antibiotics used today were discovered during the 1950s. Even when new antibiotics are made available, they rarely target priority drug-resistant bacteria and are only registered for use in a small number of countries. Of the 25 new antibiotics that entered the market between 1999 and 2014, only 12 were registered in more than 10 countries.
Research and development focus
Research and development focus
Enabling science: non-clinical science activities to support the evaluation and regulatory approval of treatments.
Formulation and manufacturing: improving drug formulations to ensure affordability, adaptability and effective distribution.
Regulatory pathways: defining pathways from initial approval to country-level submission through consultation with regulatory authorities and WHO.
Public health evidence: generating post-approval evidence for policy, guidelines and appropriate clinical use.
Sustainable access: developing appropriate-use guidance to support the sustainability of new antibiotics.
“Drug-resistant bacteria are jeopardizing most medical advances of the past century and pose an incredible threat to human health and wealth. At the same time, the broken economic model for antibiotics has led to the abandonment of the field by large pharma and the private financial sector. In light of these challenges, GARDP is a very important element to support the remaining companies in delivering much needed novel antibiotics.“
Our R&D pipeline
GARDP’s research and development pipeline outlines our activities and treatment candidates for each of our programmes, from discovery work and clinical trials to registration, access and stewardship. Download the GARDP pipeline by clicking on the graphic below
